ArriVent BioPharma filed a prospectus supplement enabling up to $250 million in common stock sales under its existing ATM program through Jefferies LLC.
Key takeaways
Filed prospectus supplement on May 11, 2026, for $250,000,000 common stock ATM offering.
Sales via Open Market Sale Agreement dated February 3, 2025, with Jefferies LLC as agent.
Tied to automatic shelf registration on Form S-3ASR (File No. 333-284661), effective February 3, 2025.
Filed Exhibit 1.1: Sales Agreement; Exhibit 5.1: Legal opinion from Mintz, Levin counsel confirming shares will be validly issued.